GlycoNex Incorporation
TWO: 4168.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mei-Chun Yang
- Headquarters
- New Taipei City, Taiwan
- IPO year
- 2012
- Market cap
- NT$2.5B
- Website
- https://www.glyconex.com.tw
Loading 4168…
Loading profile data…Frequently asked questions about 4168
What does GlycoNex Incorporation (4168.TWO) do?
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently u...
Where does 4168.TWO trade?
GlycoNex Incorporation (4168.TWO) trades on the Taipei Exchange.
What sector is 4168.TWO in?
GlycoNex Incorporation (4168.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GlycoNex Incorporation?
Mei-Chun Yang is the chief executive officer of GlycoNex Incorporation (4168.TWO).
Where is GlycoNex Incorporation headquartered?
GlycoNex Incorporation is headquartered in Taiwan.
Does 4168.TWO pay a dividend?
GlycoNex Incorporation (4168.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4168.TWO go public?
GlycoNex Incorporation (4168.TWO) completed its initial public offering in 2012.